Target intelligence / Profile preview

Expansion of CUG repeat in DMPK mRNA

Molecular classification
Other, Pathogenic toxic RNA, Disease-causing structured non-coding RNA
01

Overview

Expansion of CUG repeat in DMPK mRNA refers to an abnormally long trinucleotide (CTG/CUG) repeat expansion located in the 3′ untranslated region (UTR) of the DMPK (dystrophia myotonica protein kinase) gene transcript. In individuals with myotonic dystrophy type 1 (DM1), mutant DMPK transcripts containing several hundred to several thousand CUG repeats form stable RNA hairpins in the cell nucleus, which sequester RNA-binding proteins such as muscleblind-like 1 (MBNL1). This sequestration disrupts normal pre-mRNA splicing, leading to widespread splicing defects, impairment of mRNA export, nuclear RNA foci, stress granule formation, and ultimately multisystem pathology characteristic of DM1—including muscle weakness, cardiac defects, and cataract. The pathogenic RNA structure itself is the therapeutic target, and approaches under investigation include small molecules (e.g., Cugamycin), antisense oligonucleotides, and other modalities aimed at specifically degrading or disrupting the toxic expanded CUG repeat RNA without affecting normal DMPK function[1][2][3][4][5][6][7].

Other names
DMPK CUG repeat expansionDMPK (CUG)n expansionToxic RNA CUG repeats in DMPKr(CUG)exp in DMPK
02

Mechanism of action

Disruption or binding to expanded CUG repeat hairpin to prevent sequestration of RNA-binding proteins; RNA cleavage/degradation of toxic expanded CUG repeat transcript; Inhibition of mutant DMPK mRNA transcription

03

Biological functions

Regulation of RNA-binding proteins (e.g., sequestration of MBNL1)Pre-mRNA splicing modulation/disruptionNuclear retention of mutant RNAImpaired mRNA translationStress granule induction
04

Disease associations

Neurodegenerative diseaseMuscular dystrophyCardiac diseaseCataractMultisystem/complex disease (as in myotonic dystrophy type 1)
05

Safety considerations

Potential off-target RNA cleavage (in non-pathogenic CUG motifs)Unintended effects on splicing in normal tissuesUnknown long-term effects for RNA-targeted therapeutics in human tissues
06

Interacting drugs

Cugamycin (experimental RNA-cleaving small molecule)

2 more in the full profile.

07

Biomarkers

CUG RNA foci (by FISH or immunofluorescence in patient tissue)Sequestration or nuclear depletion of MBNL1 proteinSplicing defects in downstream target pre-mRNAs

Beyond the preview

Go deeper on Expansion of CUG repeat in DMPK mRNA.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Expansion of CUG repeat in DMPK mRNA.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call